Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) a

Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at

Analysts upgraded Replimune, Madrigal, BBB Foods, Palantir, and Fomento Economico. See other opinion

Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as

Madrigal Pharmaceuticals NASDAQ: MDGL reported second-quarter 2026 net sales of $364.3 million for R

Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript

Madrigal (MDGL) came out with a quarterly loss of $1.99 per share versus the Zacks Consensus Estimat

CONSHOHOCKEN, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL),

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Wells Fargo analyst Sadia Rahman initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) wit

CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a

CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) a

New U.S. Rezdiffra patents in F2/F3 to be listed in FDA’s Orange BookU.S. Patent No. 12,667,575, dir

Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the

These three biotechs are posting strong revenue growth. Brand-new launches and label expansions shou

CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a

/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) y su filial Ribocure Pharmaceuticals A

SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (

CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a

All three could become highly prominent biotech companies within 10 years.

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Confer

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?

CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL),

- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly preval

A wave of analyst downgrades, outlook resets and company-specific headlines pushed last week's b

HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billi

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the co

  Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quar

    On Friday morning, 155 companies achieved new lows for the year.

    Friday's morning session saw 136 companies set new 52-week highs.

  This morning 118 companies reached new 52-week highs.

Stocks That Hit 52-Week Lows On Wednesday

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Monday